During regular trading hours, there were many stocks that continued to break up to the upside. These stocks are usually going up with news.If you are looking to day trade also check out my Top 2011 Stock Gainers , Stocks to Buy 2012.You can also check previous stocks to buy reports- Right Here today.Hot stocks Today Right Here.I also have technical analysis different stocks-Right Here. Market Technical analysis Right Here
Quick Look Market Closing Price:
At the close: Dow -0.49% to 13174. S&P -0.29% to 1406. Nasdaq -0.14% to 3074.
Treasurys: 30-year +0.2%. 10-yr +0.02%. 5-yr -0.03%.
Commodities: Crude -2.14% to $106.23. Gold -1.11% to $1648.85.
Currencies: Euro -0.14% vs. dollar. Yen +0.48%. Pound +0.22%.
After Hours News:
Omnova Solutions (OMN): FQ1 EPS of $0.23 beats by $0.12. Revenue of $276M (+1.5% Y/Y) misses by $16M. Shares +14.6% AH
Oracle (ORCL) guides on its FQ3 call for FQ4 revenue growth of -2% to +2% and EPS of $0.76-$0.81 (no forex adjustments); the former is below a consensus for 3.4% growth, while the latter is largely above a $0.76 consensus. New software license revenue growth is expected to be -2% to +8% Y/Y. Hardware revenue, which was down sharply in FQ3, is expected to be flat to up $100M-$110M Q/Q. ORCL now +0.1% AH
FSI International (FSII): FQ2 EPS of $0.09 beats by $0.04. Revenue of $38.5M (+25% Y/Y) beats by $6.5M. Shares +10.4% AH
FSI International (FSII): FQ2 EPS of $0.09 beats by $0.04. Revenue of $38.5M (+25% Y/Y) beats by $6.5M. Shares +10.4% AH
Krispy Kreme Doughnuts (KKD): Q4 EPS of $0.06 misses by $0.01. Revenue of $102M (+11.2% Y/Y) in-line. Shares +5.2% AH
Jabil Circuit (JBL): FQ2 beats on both a per share an revenue basis, but warns that its FQ3 EPS will likely miss estimates. It now expects to earn between $0.49 - $0.59 per share. Consensus estimates are for an EPS of $0.58. Shares -2.2% AH.
Ariad Pharmaceuticals (ARIA) -1.7% AH after an FDA panel votes13-1 not to recommend Taltorvic, a sarcoma drug developed by Ariad and Merck (MRK). The panel concluded Taltorvic's short-term benefits fail to "outweigh the risks of adverse reactions and a lack of evidence of improved overall survival." A rival drug from GlaxoSmithKline (GSK) received a thumbs-up earlier today.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/
